INTRODUCTION

The newly identified coronavirus disease COVID-19 spread quickly across China and other nearby countries. To date, more than 221 countries have been affected by this pandemic, with more than 519 million infected patients reported, leading to more than 6.2 million deaths worldwide.1

Although fever and cough are known to be the most prevalent symptoms, severe cases of COVID-19 infection are characterized by acute respiratory failure requiring early oxygen therapy and intensive care (ICU) admission. In fact, up to 5% of SARS-CoV-2-infected patients develop severe acute hypoxicemic respiratory failure requiring ICU admission as well as non-invasive and/or invasive mechanical ventilation as supportive treatment.2 In the ICU, biomarkers are used as adjunctive tools in clinical decision-making in various infectious diseases.3 Indeed, many studies have shown that elevated levels of C-reactive protein, leukocytes, and procalcitonin (PCT) in patients admitted with COVID-19 were significantly associated with higher risks of nosocomial infection and death.3–6

As a consequence, it is now accepted that these biomarkers might aid in prognostic risk stratification of patients with COVID-19 infection. On the other hand, serum cholinesterase (SChE) plays an important role in the inflammatory response and may be associated with prognosis in sepsis.7 In fact, it is well established that decreased SChE activity can be used as a reliable diagnostic biomarker for septic shock7 and that SChE activity level can be used as a prognostic biomarker in septic shock.8,9

However, there are few data published about this biomarker in patients suffering from a severe COVID-19 infection requiring ICU admission. In fact, and to the best of our knowledge, with the exception of only one study suggesting that a patient’s SChE activity level on admission may be a useful predictor of severity and prognosis,10 there are no other published data on this biomarker with this specific condition. In the current study, we aimed to evaluate the prognostic value of the SChE activity in SARS-CoV-2–infected patients with respiratory failure requiring ICU admission. The primary endpoint was the association between the value of the lowest SChE and the mortality. The secondary endpoint was the association between the value of SChE and severity of illness, the development of nosocomial infection, and the correlation between the SChE activity and other biomarkers of sepsis on ICU admission and during the ICU stay.

METHODS

Study design and setting. This study was approved by the internal institutional review board (CPP SUD No. 0384/2022), and the requirement for written informed consent was waived by the ethics committee. It was a retrospective study of severe, critically ill adult COVID-19 patients, all of whom had a confirmed SARS-CoV-2 infection, admitted into the ICU of a university hospital between September 1 (the first case) and January 15, 2021, for acute respiratory failure. In the current study, a power calculation was not performed; as a consequence, we used the number of patients available for this analysis.

The positive diagnosis of SARS-CoV-2 infection was confirmed by reverse transcription polymerase chain reaction (RT-PCR) test in all cases. We included all patients who were admitted to our ICU and whose levels of SChE activity were explored on ICU admission and during ICU stay. Other inflammatory biomarkers (CRP, PCT, and leukocytes) were also analyzed. SChE level was measured in fresh serum that had not been frozen and thawed using a biochemistry analyzer (Cobas 6000 Analyzer, model c501) with the spectrophotometric method. The normal range of the values varies from 5.320 to 12.290 IU/L. PCT was measured with the electrochemiluminescence method using a Cobas 6000 Analyzer.
SERUM CHOLINESTERASE ACTIVITY IN SEVERE COVID-19-INFECTED PATIENTS

RESULTS

Clinical and biological findings of the entire population group. During the study period, 178 patients were admitted into our ICU for acute respiratory distress due to SARS-CoV-2 infection. Forty-one patients were excluded because SCH activity level was not recorded on ICU admission. As a result, only 137 patients were included. There were 100 male and 37 female patients. Mean age was 62.6 ± 12.3 with a median of 65 years. Fifty-three patients (38.6%) were obese with a BMI > 30 kg/m², and 111 patients (81%) had one or more comorbidities. The most commonly observed comorbidities were arterial hypertension in 65 patients (47.4%), diabetes mellitus in 62 (45.3%), and chronic obstructive pulmonary disorder in 13 (9.5%). The most common symptoms observed on hospital admission were dyspnea in 127 patients (92.7%), fever (≥ 38°C) in 88 (64.2%), and cough in 84 (61.8%). The mean time from the onset of symptoms to ICU admission was at 10.9 ± 5.5 days.

On ICU admission, all the patients had major signs of respiratory distress. The mean respiratory rate was at 30 ± 11 breaths per minute; the mean oxygen saturation measured by pulse oximetry (SpO₂) was at 87 ± 11% (under oxygen support via facial mask). The mean body temperature was at 37 ± 0.8°C; fever (≥ 38°C) was observed in only 20 patients (14.5%). Moreover, 16 patients (11.6%) developed shock and the use of vasopressor (norepinephrine) was required in all these cases. The mean PaO₂/FiO₂ ratio was at 100 ± 58 with a median at 82. It was < 200 in 128 patients (93.4%). On the day of ICU admission, oxygen therapy was required for all patients (100%), via facial mask for 109 (79.6%), noninvasive mechanical ventilation for 82 (60%), and high-flow nasal oxygen for 57 (41.6%). Invasive mechanical ventilation was applied in 28 patients on the day of ICU admission and in 64 (46.7) during ICU stay. The mean pH on ICU admission was at 7.39 ± 0.10, ranging from 6.90 to 7.58. Among the inflammatory parameters recorded on ICU admission for patients with available data, the mean value of leukocytes was at 13,650 ± 5,960 cells/mm³. Mean CRP was at 120 ± 106 mg/mL, it was ≥ 100 mg/L in 42% of the cases. The mean procalcitonin was at 2.46 ± 10 ng/mL, ranging from 0.1 to 100 ng/mL. Finally, the mean of SCH activity was at 5,656 ± 1,818 IU/L (range: 1,926–11,192 IU/L). Table 1 summarizes all the clinical and biological findings of the entire population group on ICU admission. During their ICU stay, 63 patients (46%) developed shock requiring the use of vasopressor (norepinephrine), 78 developed renal failure (57%), 64 (46.7%) required the use of invasive mechanical ventilation, and 63 (46%) developed nosocomial infections. Corticosteroids (dexamethasone, 12–24 mg/day) were given to 130 patients (95%), and preventive and/or therapeutic anticoagulation for venous thromboembolism were used in 136 patients (99%). However, remdesivir/tocilizumab was not used during the study period.

The most observed nosocomial infections were ventilator-associated pneumonia in 38 patients (28%), urinary tract infection in 12 (9%), and septicemia in 7 (5.1%). During their ICU stay, 74 patients (54%) died, with an average time from ICU admission to death at 9.7 ± 6.4 days (median: 8 days). Thirty-four patients (25%) died within 7 days after ICU admission, of whom 21 had developed nosocomial infections. On the other hand, 40 patients (29.2%) died after 7 days of ICU admission, of whom 27 had developed nosocomial infections.
The mean duration of ICU stay was at 8.4 ± 5.9 days. Supplemental Table 1 shows the comparison between patients according to the severity of the ARDS. Supplemental Table 2 shows the comparison between the Survivors and Deaths groups according to the severity of the ARDS.

**Prognostic value of the SChE activity on ICU admission.**

The comparison between two groups (Survivors and Deaths) on ICU admission showed that the SChE activity is significantly lower in nonsurvivors (6,238 ± 1,823 versus 5,138 ± 1,655 IU/L; P < 0.001). A value of SChE activity < 6,000 IU/L was associated with a severe outcome with sensitivity at 71%, specificity at 87%, and an AUC at 0.80 (95% confidence interval [CI]: 0.70–0.87) (Figure 2). Multivariate analysis showed that factors associated with poor outcomes were: age > 65 years (P = 0.016; odds ratio [OR]: 8.3; 95% CI: 1.49–46.4), the use of mechanical ventilation (P < 0.001; OR: 37; 95% CI: 5.89–134.3), and a value of SChE activity

![FIGURE 1. Lowest serum cholinesterase activity (nadir) stratified by outcome. This figure appears in color at www.ajtmh.org.](image-url)
lower than 5,000 IU/L ($P = 0.037$; OR: 6.3; 95% CI: 1.12–35.90).

We found that the value of SCHe activity was significantly lower in the group of patients who developed septic shock requiring the use of vasopressor (5,711 ± 1,975 versus 4,057 ± 1,144 IU/L; $P < 0.001$) and nosocomial infection (5,772 ± 1,869 versus 3,986 ± 1,241 IU/L; $P < 0.001$) (Figure 3). The value of SCHe activity was significantly correlated with the severity of hypoxemia and the PaO2/FiO2 ratio ($P = 0.003$; $r = 0.25$).

Finally, we found a significant correlation between the nadir of SCHe activity (lowest value) recorded during ICU stay and the nadir recorded for other biomarkers of sepsis—in particular, with CRP ($P < 0.001$; $r = -0.38$) and procalcitonin ($P = 0.04$; $r = -0.17$).

DISCUSSION

Our study showed that the SCHe activity might be used as a new biomarker that helps in the prognostic risk stratification of patients with COVID-19 infection. In fact, we found that a low value of SCHe activity recorded on ICU admission and during ICU stay was associated with a poor prognosis in univariate (in all studied population and in each subtype of ARDS: mild, moderate, and severe) and multivariate analyses. Moreover, we found a significant association between the SCHe activity on ICU admission and the severity of illness (SAPS II and SOFA score). We found again a significant correlation between the value of SCHe activity and the development of nosocomial infection. Finally, we found a significant correlation between the SCHe activity and other biomarkers of sepsis on ICU admission and during ICU stay. These significant correlations confirm that this biomarker could help prediction, together with other markers (biomarkers and digital markers such as SAPS, SOFA, and ARDS severity), to predict outcome. In fact, in our study, an SCHe activity < 5,000 IU/L was associated with a poor outcome with high sensitivity and specificity. The cost of this biomarker is low (< $5), and it is usually used in the diagnosis and management of organophosphate poisoning, particularly in low- and middle-income countries.

It has been established that many inflammatory (procalcitonin, CRP) and biochemical (troponin I, lactate dehydrogenase, D-dimer, gamma-glutamyl transferase) biomarkers are significantly associated with a severe form of COVID-19 infection. Moreover, it has already been established that elevated levels of CRP, leukocytes, and PCT in patients admitted with COVID-19 are significantly associated with a higher risk of nosocomial infection and death in SARS-CoV-2–infected patients. However, the correlation between the cholinesterase activity and the severity of COVID-19 pneumonia is not often reported. In fact, and to the best of our knowledge, only one study investigated this association exclusively. Indeed, Nakajima et al. found in their study that cholinesterase levels on admission were significantly associated (326 versus 218 IU/L, $p = 0.006$) with the severity of COVID-19 pneumonia in 26 patients with confirmed COVID-19 infection. They found again that cholinesterase levels on admission were significantly lower in the Deaths group than in the Survivors group. The authors concluded that the SCHe activity may reflect the disease state of COVID-19 pneumonia and suggest that the cholinesterase level on admission may be used as one of the predictors of severity and prognosis. In one retrospective study analyzing the clinical, radiological, and biological characteristics, and the outcome of critically ill patients admitted to the ICU for acute respiratory failure following COVID-19 infection, we found that SCHe activity lower than 5,000 IU/L was associated with a severe outcome. However, this study included only 96 patients, among whom only 78 patients had an SCHe activity recorded on ICU admission. In the current study, a total of 178 patients were admitted into our ICU for respiratory distress due to COVID-19 infection. However, only 137 patients were included because 41 patients were excluded because the level of the SCHe activity was not recorded on ICU admission. The impact outcome of the
lowest value of SCHE activity is more extensively studied in the current study. In fact, we have analyzed the association between the SCHE activity on ICU admission and the severity of illness (SAPS II and SOFA score). In the current study, we found that the SCHE activity may reflect the disease state of COVID-19 pneumonia; therefore, we suggest that the cholinesterase level on admission and during ICU stay may be used as one of the predictors of severity and prognosis. We also found a significant correlation between the value of SCHE activity and the development of nosocomial infection, the development of shock, and the other biomarkers of sepsis on ICU admission and during ICU stay.

Recently, it was established that a decreased SCHE activity can be used as a diagnostic biomarker for septic shock and bacterial infection. The pathophysiology of the decline of the SCHE activity in septic patients is not well understood, and several hypotheses have been postulated. In all cases, the role of inflammatory reaction is well established. The first hypothesis is reduced synthesis of SCHE due to bacterial and/or viral infection. The second is the increase of SCHE catabolism and the inhibition of SCHE by inflammatory mediators (cytokines). In patients suffering from severe COVID-19 pneumonia requiring ICU admission, the infection of alveolar units by the SARS Cov-2 virus leads to diffuse alveolar damage with an important inflammatory response and a secondary cytokine (tumor necrosis factor-α and interleukin-6) storm leading to inhibition of SCHE. Another mechanism should be considered in severely SARS-CoV-2 infected patients: the severity of hypoxemia leading to liver injury and afflication. We found a significant correlation between the value of the SCHE activity and the severity of hypoxemia and the PaO₂/FiO₂ ratio (P = 0.003; r = 0.25). In our study, although most patients received corticosteroids and anticoagulation (95% and 99%, respectively), the major-ity exhibited a severe inflammatory response triggered by SARS-COV-2. This confirms the severity of this inflammatory response; in fact, like corticosteroids, anticoagulants were found to have an interesting antiinflammatory action.

Finally, we acknowledge that our study suffers has limitations. All retrospective studies suffer from incomplete information. CRP and PCT tests were not performed for all patients at ICU admission. Moreover, the time that SCHE activity nadir was determined was not the same for all patients. The number of patients that could not be included was high, which can cause bias in interpretation of the results.

However, our study is one of the few studies that has dealt with the prognostic impact of the SCHE activity in patients suffering from severe COVID-19 infection with acute respiratory failure. Consequently, we think that SCHE activity can be used in the screening of severe patients in ICU and in the emergency department because it is correlated with routinely monitored inflammatory parameters. Moreover, the reduction in the SCHE activity appears significantly earlier (within 1–2 hours after onset of inflammation or sepsis) than those of routinely measured inflammatory biomarkers. Finally, we recommend routine monitoring of SCHE activity in the ICU because the SCHE activity level has been used as a prognostic biomarker in other studies, particularly for septic shock.

CONCLUSION

Our study shows that the low SCHE activity is associated with a poor outcome, development of nosocomial infections, and illness severity. It might be used as a new biomarker to help in the prognostic risk stratification of patients with COVID-19 infection. Further studies for external validation of our findings are needed on this subject.

Received September 1, 2021. Accepted for publication May 20, 2022.

Note: Supplemental tables appear at www.ajtmh.org.

Acknowledgments: We thank Mr. Chokri Khalaf for revising our manuscript. The American Society of Tropical Medicine and Hygiene has waived the Open Access fee for this article due to the ongoing COVID-19 pandemic and has assisted with publication expenses.

Authors’ addresses: Mabrouk Bahloul, Sana Kharrat, Saba Makni, Najeh Baccouche, Rania Ammar, Olfia Turki, Chokri Ben Hamida, Hedi Chelly, Kamilia Chtara, Fatma Ayedi, and Mourin Bouazziz, Department of Intensive Care, Habib Bourguiba University Hospital, University of Sfax, Sfax, Tunisia, E-mails: bahloumlab@yahoo.fr, sanakharatt15@hotmail.com, saba.makni@rns.tn, baccouchnejah@gmail.com, rania.ammazayani@gmail.com, ofla.turki.rea@gmail.com, chokri_benhamida@yahoo.fr, hedi.chelly@rns.tn, kamilia.chtaraelaoud@gmail.com, fatma.ayedi@rns.tn, and mourin.bouazziz@rns.tn. Aida Eleuch, Biochemistry Laboratory, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia, E-mail: aidaeleuch@gmail.com. Lamia Bennajah and Ameen Chitrouou, Laboratory of Microbiology, Habib Bourguiba University Hospital, Faculty of Medicine, University of Sfax, Sfax, Tunisia, E-mails: lamiasfax2003@yahoo.fr and ame11.doc@gmail.com. Fatma Ayedi, Department of Intensive Care, Habib Bourguiba University Hospital, Sfax, Tunisia, E-mail: fatma.ayedi@rns.tn.

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Worldometer. Coronavirus Update. Available at: https://www.worldometers.info/coronavirus/. 2. Bahloul M et al., 2020. Pulmonary capillary leak syndrome following COVID-19 virus infection. J Med Virol. doi:10.1002/jmv.26152. 3. Di Maria E, Latini A, Borgiani P, Novelli G, 2020. Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis. Hum Genomics 14: 30. 4. Malisz P et al., 2020. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evidence-Based Med. doi:10.1136/bmjebm-2020-111536. 5. Danwang C et al., 2020. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19), Biomark Res 8: 37. 6. Hodges G et al., 2020. Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study. BMJ Open 10: e041295. 7. Bahloul M, Baccouch N, Chtara K, Turki M, Turki O, Hamida CB, 2017. Value of serum cholinesterase activity in the diagnosis of septic shock due to bacterial infections. J Intensive Care Med 32: 346–352. 8. Zivkovic AR, Decker SO, Zimstein AC, Sigl A, Schmidt K, Weigand MA, Hofer S, Brenner T, 2018. A sustained reduction in serum cholinesterase enzyme activity predicts patient outcome following sepsis. Mediators Inflamm 2018: 1942193. 9. Peng ZL, Huang LW, Yin J, Zhang KN, Xiao K, Qing GZ, 2018. Association between early serum cholinesterase activity and 30-day mortality in sepsis-3 patients: a retrospective cohort study. PLoS One 13: e0203128. 10. Nakajima K et al., 2021. Serum cholinesterase associated with COVID-19 pneumonia severity and mortality. J Infect 82: 282–327.
11. Purnell JQ, 2018. Definitions, Classification, and Epidemiology of Obesity. Endotext. Available at: https://www.ncbi.nlm.nih.gov/books/NBK279167.

12. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG, on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine, 1996. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22: 707–710.

13. Le Gall JR, Lemeshow S, Saulnier F. 1993. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270: 2957–2963.

14. Vincent J et al., 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302: 2323–2329.

15. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS, ARDS Definition Task Force, 2012. Acute respiratory distress syndrome: the Berlin definition. JAMA 307: 2526–2533.

16. Vincent JL, De Backer D, 2013. Circulatory shock. N Engl J Med 369: 1726–1734.

17. Hanley JA, McNeil BJ, 1983. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839–843.

18. Brahmi N, Mokline A, Kouraichi N, Ghorbel H, Bie1 Y, Thabet H, Hedhil A, Amamou M, 2006. Prognostic value of human erythrocyte acetyl cholinesterase in acute organophosphate poisoning. Am J Emerg Med 24: 822–827.

19. de Guadiana-Romualdo LG et al., 2021. Cardiac troponin and COVID-19 severity: results from BIOCOVID study. Eur J Clin Invest 52: e13532.

20. Mueller C, Giannitsis E, Jaffe AS, Huber K, Mair J, Cullen L, Hammarsten O, Mills NL, Mockel M, Krychtiuk K, Thygesen K, Lindahl B, ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association, 2021. Cardiovascular biomarkers in patients with COVID-19. Eur Heart J Acute Cardiovasc Care. doi: 10.1093/ehjacc/zuab009.

21. Bahloul M et al., 2022. Clinical characteristics and outcomes of critically ill COVID-19 patients in Sfax, Tunisia. Acute Crit Care 37: 84–93.

22. Vetter A, Vu DL, L’Huillier AG, Schibler M, Kaiser L, Jacquerioz F, 2020. Clinical features of COVID-19. BMJ 2020: 369.

23. Mousavi S, Moradi M, Khorsheidhamad T, Motamed M, 2015. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci 2015: 507151.

24. Zivkovic AR, Bender J, Brenner T, Hofer S, Schmidt K, 2016. Reduced butyrylcholinesterase activity is an early indicator of trauma-induced acute systemic inflammatory response. J Inflamm Res 9: 221–230.